Overview

Anamorelin Study for Advanced Pancreatic Cancer

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 subjects with advanced PDAC and cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 25 weeks. Subjects will be instructed to take the study drug at least 1 hour before their first meal of the day
Phase:
Phase 2
Details
Lead Sponsor:
Lahey Clinic
Collaborators:
Helsinn Healthcare SA
Quartesian LLC